MGT SVCS/CONTRACT & PROCUREMENT SUP

为了解决神经系统疾病缺乏有效治疗的问题，美国国立卫生研究院建立了蓝图神经治疗网络(http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm).该计划旨在通过临床第一阶段成功开发药物，并促进行业合作伙伴关系，使其充分发展。这一重大挑战的长期目标是至少生产一种新的有效药物来治疗目前治疗不当或未治疗的神经系统疾病。NIH蓝图神经治疗网络正在建立一个由具有丰富行业经验的合同服务提供商和顾问组成的虚拟制药网络，以支持NIH神经科学研究社区的药物开发。该网络为神经科学研究人员提供全方位的行业风格的药物开发服务和专业知识，包括药物化学、支持IND的研究和第一阶段临床试验基础设施。神经治疗计划的药理学和毒理学(PTNP)合同支持所有临床前药理学和毒理学测试，以提供线索优化和选择临床候选药物所需的信息，以及FDA为允许对新化学实体进行临床评估而提出的研究性新药(IND)申请所需的全面研究。

To address the paucity of effective treatments for disorders of the nervous system, the NIH has established the Blueprint Neurotherapeutics Network (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). This program intends to develop drugs successfully through clinical Phase I and facilitate industry partnerships for their full development. The long-term goal of this grand challenge is to produce at least one novel and effective medication for a disorder of the nervous system that is currently poorly treated or untreated. The NIH Blueprint Neurotherapeutics Network is establishing a ¿virtual pharma¿ network of contract service providers and consultants with extensive industry experience to enable drug development in the NIH neuroscience research community. The Network offers neuroscience researchers access to a full range of industry-style drug development services and expertise, including medicinal chemistry, IND-enabling studies, and Phase 1 clinical trial infrastructure. The Pharmacology and Toxicology for Neurotherapeutics Program (PTNP) contracts support all preclinical pharmacology and toxicology testing needed to inform lead optimization and the selection of a clinical candidate, and comprehensive studies needed for an Investigational New Drug (IND) application for the FDA to allow for clinical evaluation of New Chemical Entities.